Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing

Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) and bladder cancer with clinical benefit. Nevertheless, many patients failed to respond to anti-PD-1/PD-L1 treatment, so it...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Acta Pharm Sin B
Auteurs principaux: Wang, Zhiru, Kang, Wenting, Li, Ouwen, Qi, Fengyu, Wang, Junwei, You, Yinghua, He, Pengxing, Suo, Zhenhe, Zheng, Yichao, Liu, Hong-Min
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982505/
https://ncbi.nlm.nih.gov/pubmed/33777676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.11.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires